Researchers examine apixaban’s impact on dialysis sufferers at Nationwide Taiwan College Hospital. Credit score: Nationwide Taiwan College
A latest examine from Nationwide Taiwan College Hospital exhibits that apixaban, a blood-thinning medicine, can assist forestall blood clots in dialysis sufferers after a process to clear blocked vascular entry. Dialysis sufferers depend on vascular entry—like fistulas or grafts—to filter their blood, however clots can type and block these pathways, making dialysis unimaginable.
The analysis staff examined whether or not apixaban may cease these clots from coming again after a thrombectomy, a process to take away the blockage. The examine included 186 sufferers break up into two teams. One group obtained commonplace care, whereas the opposite bought commonplace care plus apixaban (2.5 mg twice every day) for 3 months. After three months, the apixaban group had fewer clot recurrences—24% in comparison with 41% in the usual care group. This implies apixaban minimize the clot threat by practically half.
It additionally improved the possibilities of maintaining the vascular entry working with out additional points (32% failure charge versus 50% within the management group). These advantages lasted as much as six months, although the medicine was solely used for 3. Security-wise, apixaban did not improve critical bleeding in comparison with commonplace care, although minor bleeding—like pores and skin or gum bleeds—was extra frequent (23% versus 8%). Most minor bleeds have been manageable and did not require stopping the drug.
The findings, printed in Kidney Worldwide, counsel apixaban may very well be a useful choice for dialysis sufferers after thrombectomy, balancing clot prevention with acceptable dangers. “This study offers hope for dialysis patients by showing apixaban can safely reduce clot risks,” stated Prof. Mu-Yang Hsieh.
Extra info:
Tsung-Yu Ko et al, A randomized managed trial evaluated the efficacy and security of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular entry, Kidney Worldwide (2024). DOI: 10.1016/j.kint.2024.10.023
Offered by
Nationwide Taiwan College
Quotation:
Apixaban reduces clot threat in dialysis sufferers after vascular process: Examine (2025, March 24)
retrieved 25 March 2025
from https://medicalxpress.com/information/2025-03-apixaban-clot-dialysis-patients-vascular.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
